Compare CTSO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | CLRB |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 24.5M |
| IPO Year | 2008 | 2008 |
| Metric | CTSO | CLRB |
|---|---|---|
| Price | $6.01 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.25 | $11.50 |
| AVG Volume (30 Days) | 52.9K | ★ 148.1K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,503,908.00 | N/A |
| Revenue This Year | $4.91 | N/A |
| Revenue Next Year | $13.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.30 | $1.12 |
| 52 Week High | $7.44 | $4.70 |
| Indicator | CTSO | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 73.08 | 25.04 |
| Support Level | $2.88 | N/A |
| Resistance Level | $7.44 | $3.03 |
| Average True Range (ATR) | 0.61 | 0.16 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 82.52 | 12.69 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.